The biotech firm reports Q1 2026 revenue of $9.7 million, in line with expectations, as it outlines growth plans.
MaxCyte announced a 2026 revenue outlook of $30 million to $32 million, aligning with its long-term growth strategy. The company also authorized a $10 million share repurchase program, signaling confidence in its financial position.
In Q1 2026, MaxCyte reported total revenue of $9.7 million, including $6.2 million in core revenue and $3.4 million from milestone and royalty payments. Management stated the results met internal expectations, reflecting steady progress in its cell therapy platform.
The $10 million buyback program follows a period of operational execution, with leadership emphasizing stability in its revenue streams. The outlook and repurchase plan suggest a focus on shareholder value amid ongoing expansion.